THTX - Theratechnologies to Present Long-Term Efficacy Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting | Benzinga
- First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid tumors
- Part 3 of Phase 1 trial in advanced ovarian cancer is ongoing
MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will present long-term efficacy, safety and pharmacokinetic (PK) data on the use of its lead investigational peptide-drug conjugate (PDC) candidate, TH1902 (sudocetaxel zendusortide), in patients with solid tumors. The Company will present the long-term data in a poster session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which takes place May 31-June 4, 2024, in Chicago, IL.
The ASCO poster represents the first presentation of long-term data from Part 1 (dose escalation) and Part 2 (dose expansion) of Theratechnologies' Phase 1 clinical trial of sudocetaxel zendusortide in individuals with solid tumors, following preliminary evidence of antitumor activity presented at the 2023 ASCO annual meeting. This updated analysis will present further data on long-term efficacy, safety and PK from Parts 1 and 2, focusing specifically on patients receiving sudocetaxel zendusortide at a dose of 300 mg/m2 every three weeks. Patients in this dosing group have cancers with known high expression of sortilin (SORT1), including ovarian cancer, endometrial cancer, triple-negative breast cancer (TNBC) and melanoma. Part 3 (dose optimization) of the Phase 1 trial, in patients with advanced ovarian cancer, is ongoing.
"We have eagerly awaited the updated analysis from Parts 1 and 2 of the Phase 1 trial, as it will provide our first evidence of the long-term effects of sudocetaxel zendusortide in patients with solid tumors," said Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer at Theratechnologies. "These safety, efficacy and pharmacokinetics data are particularly timely, in that they will provide valuable context as we continue to evaluate this novel peptide-drug conjugate in Part 3 of this ongoing trial."